Handelsbanken Fonder Ab Madrigal Pharmaceuticals, Inc. Transaction History
Handelsbanken Fonder Ab
- $26.2 Billion
- Q4 2024
A detailed history of Handelsbanken Fonder Ab transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 32,800 shares of MDGL stock, worth $11.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
32,800
Previous 32,500
0.92%
Holding current value
$11.2 Million
Previous $6.9 Million
46.74%
% of portfolio
0.04%
Previous 0.03%
Shares
9 transactions
Others Institutions Holding MDGL
# of Institutions
298Shares Held
21.9MCall Options Held
819KPut Options Held
644K-
Janus Henderson Group PLC London, X02.48MShares$843 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$694 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$690 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$678 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$671 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.81B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...